title: [18F]FLT PET for diagnosis and staging of thoracic tumours.
abstract: The nucleoside analogue 3'-deoxy-3'-[18F]fluorothymidine (FLT) has been introduced for imaging of tumour cell proliferation by positron emission tomography (PET). This study evaluated the use of FLT in patients with thoracic tumours prior to treatment. Whole-body FLT PET was performed in 16 patients with 18 tumours [17 thoracic tumours (nine non-small cell lung cancers, five oesophageal carcinomas, two sarcomas, one Hodgkin's lymphoma) and one renal carcinoma] before treatment. Fluorine-18 fluorodeoxyglucose (FDG) PET was performed for comparison except in those patients with oesophageal carcinoma. For semi-quantitative analysis, the average and maximum standardised uptake values (avgSUV and maxSUV, respectively) (FLT, 114+/-20 min p.i.; FDG, 87+/-8 min p.i.; 50% isocontour region of interest) was calculated. All 17 thoracic tumours and 19/20 metastases revealed significant FLT accumulation, resulting in easy delineation from surrounding tissue. The additional small grade 1 renal carcinoma was not detected with either FLT or FDG. In most lung tumours (avgSUV 1.5-8.2) and metastases, FLT showed intense uptake. However, one of two spinal bone metastases was missed owing to the high physiological FLT uptake in the surrounding bone marrow. Oesophageal carcinoma primaries (avgSUV 2.7-10.0) and occasional metastases showed particularly favourable tumour/non-tumour contrast. Compared with FDG, tumour uptake of FLT was lower (avgSUV, P=0.0006; maxSUV, P=0.0001), with a significant linear correlation (avgSUV, r2=0.45; maxSUV, r2=0.49) between FLT and FDG. It is concluded that FLT PET accurately visualises thoracic tumour lesions. In the liver and the bone marrow, high physiological FLT uptake hampers detection of metastases. On the other hand, FLT may be favourable for imaging of brain metastases owing to the low physiological uptake.
authors.affiliation: Department of Nuclear Medicine, Eberhard-Karls-University Tübingen, Tübingen, Germany. helmut.dittmann@med.uni-tuebingen.de
authors.forename: Helmut
authors.initials: H
authors.lastname: Dittmann
authors.forename: Bernhard Matthias
authors.initials: BM
authors.lastname: Dohmen
authors.forename: Frank
authors.initials: F
authors.lastname: Paulsen
authors.forename: Kai
authors.initials: K
authors.lastname: Eichhorn
authors.forename: Susanne Martina
authors.initials: SM
authors.lastname: Eschmann
authors.forename: Marius
authors.initials: M
authors.lastname: Horger
authors.forename: Manfred
authors.initials: M
authors.lastname: Wehrmann
authors.forename: Hans Juergen
authors.initials: HJ
authors.lastname: Machulla
authors.forename: Roland
authors.initials: R
authors.lastname: Bares
mesh_terms: D000328:Adult; D000368:Aged; D015224:Dideoxynucleosides; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging / Q000379:methods; D009382:Neoplasms, Unknown Primary / Q000175:diagnosis / Q000000981:diagnostic imaging* / Q000473:pathology; D019275:Radiopharmaceuticals; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D013899:Thoracic Neoplasms / Q000175:diagnosis / Q000000981:diagnostic imaging* / Q000473:pathology / Q000556:secondary*; D014055:Tomography, Emission-Computed / Q000379:methods*
chemical_list: D015224:Dideoxynucleosides; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18; C002854:alovudine